Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China · Delayed Price · Currency is CNY

65.91

+0.29 (0.44%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Drugs and Drug Abuse Category					82.09M	60.71M	33.33M
Drugs and Drug Abuse Category Growth					35.23%	82.12%	-
Infectious Disease Detection					64.29M	42.03M	20.93M
Infectious Disease Detection Growth					52.96%	100.81%	-
Women's Health Testing					15.58M	10.12M	7.32M
Women's Health Testing Growth					53.87%	38.23%	-
Cardiac Marker Detection					4.74M	5.08M	3.59M
Cardiac Marker Detection Growth					-6.67%	41.56%	-
Tumor Detection Class					6.33M	3.53M	2.23M
Tumor Detection Class Growth					79.33%	58.64%	-
Other Testing					11.15M	8.25M	8.30M
Other Testing Growth					35.26%	-0.61%	-
Total					184.19M	129.72M	75.70M
Total Growth					41.99%	71.36%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Overseas	819.10M	-					182.70M	127.84M	-
Overseas Growth	-	-					42.91%	-	-
China	43.27M	-					1.49M	1.88M	3.10M
China Growth	-	-					-20.90%	-39.38%	-
Europe	-	-					-	-	36.01M
Asia	-	-					-	-	22.63M
Americas	-	-					-	-	6.19M
Africa	-	-					-	-	7.29M
Oceania	-	-					-	-	485.10K
Total	862.37M	-					184.19M	129.72M	75.70M
Total Growth	-	-					41.99%	71.36%	-

Source: S&P Global Market Intelligence.